Ipamorelin Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Ipamorelin?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Growth hormone secretion, bone density, gastrointestinal motility, body composition, metabolic function
• First Developed: Late 1990s by Novo Nordisk; clinical development continued by Helsinn Therapeutics
• Molecular Weight: 711.85 g/mol
• Research Status: Extensive preclinical data; one Phase I and one Phase II human trial completed
• Key Mechanisms: GHSR-1a agonism, pulsatile GH release, cAMP/PKA signaling, IGF-1 axis activation
• Published Studies: Foundational selectivity data established 1998; preclinical studies in swine, rat, and murine models; two registered clinical trials
• Clinical Trial Status: Phase II trial for postoperative ileus failed primary endpoint; no further registered clinical development
• Regulatory Classification: Not approved for human therapeutic use; research use only; ipamorelin acetate was previously on FDA Category 2 compounding list before nomination withdrawal in September 2024

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide, meaning it is built from five amino acid units, developed originally by Novo Nordisk in the late 1990s. Unlike naturally occurring peptides in the body, ipamorelin incorporates non-natural amino acids that improve its stability and sharpen its targeting of a single receptor. Its development marked a meaningful advance in growth hormone secretagogue research because it stimulates GH release without the hormonal side effects that compromised earlier compounds in the same class.

The research interest in ipamorelin centers on selectivity. Earlier growth hormone-releasing peptides, particularly GHRP-6 and GHRP-2, triggered GH release effectively but also elevated cortisol, ACTH, and prolactin, hormones whose elevation creates confounding variables in research and unwanted physiological effects in clinical use. Ipamorelin does not produce these elevations, even at doses exceeding 200 times the effective GH-releasing dose in animal models. This profile earned it the description of the first GHRP-like agonist with GHRH-level selectivity when the foundational data were published in 1998 [1].

Clinical development shifted to Helsinn Therapeutics, which investigated ipamorelin for postoperative ileus, a condition in which gut motility fails to recover normally after abdominal surgery. The gastrointestinal application was a logical extension of preclinical data showing that ipamorelin restores gut motility in animal surgery models. That Phase II trial enrolled 117 patients but did not demonstrate a statistically significant benefit on its primary endpoint, and clinical development was discontinued [2].

Both the preclinical promise and the Phase II failure are important context for understanding ipamorelin peptide research today. The compound remains scientifically interesting as a research tool for studying the GH axis and its downstream effects on metabolism, bone, and body composition. It is classified for research use only and is not approved for human therapeutic applications in any jurisdiction.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Ipamorelin’s five-residue sequence contains three non-natural amino acids that are central to its research profile. The first residue, alpha-aminoisobutyric acid (Aib), replaces a standard amino acid with a methylated version that resists enzymatic cleavage. The second non-natural residue, D-2-naphthylalanine (D-2-Nal), is a bulky aromatic amino acid incorporated in its D-configuration, meaning it is the mirror image of the amino acids that appear in natural proteins. D-phenylalanine at the fourth position provides another D-configuration residue. Together, these structural choices block the peptidase enzymes that rapidly degrade natural peptides, extending ipamorelin’s plasma half-life to approximately two hours compared to the minutes-long stability of many natural peptides [1,3].

The C-terminal amide group (-NH2) replacing the usual carboxylic acid (-COOH) further stabilizes the compound and improves receptor binding affinity. This modification is common in synthetic peptide design because terminal carboxylic acids are recognized by exopeptidases that degrade natural peptides from their ends.

The absence of a central dipeptide motif found in GHRP-6 and GHRP-2 contributes to ipamorelin’s selectivity. That structural region in the earlier compounds appears to account for their off-target stimulation of cortisol and ACTH pathways. Ipamorelin’s modified sequence activates the ghrelin receptor effectively while avoiding those off-target interactions [1].

Mechanisms of Action Being Investigated

Ipamorelin acts through a single primary receptor, the growth hormone secretagogue receptor 1a (GHSR-1a), also called the ghrelin receptor. Its mechanism is more precisely characterized than many research peptides, owing to the clinical development work conducted in the late 1990s and early 2000s.

GHSR-1a Agonism and Receptor Pharmacology

GHSR-1a is expressed predominantly on somatotroph cells in the pituitary gland and on neurons in the hypothalamus. These are the cells responsible for producing and releasing growth hormone in response to appropriate signals. Ipamorelin binds this receptor with an EC50 of approximately 1.3 nmol/L in rat pituitary cells, a potency essentially equivalent to GHRP-6 despite the structural differences between the two compounds [1].

The receptor couples to Gαq/11 proteins, initiating intracellular signaling through two parallel routes. The first increases cyclic AMP (cAMP) production and activates protein kinase A (PKA) in pituitary somatotrophs and in GHRH-secreting hypothalamic neurons. The second raises intracellular calcium concentrations, which triggers calcium-dependent exocytosis, the process by which somatotroph cells release pre-packaged GH into circulation [1,3].

Pulsatile GH Release and Physiological Mimicry

One of the properties researchers find most relevant about ipamorelin is that it produces GH release in a pattern resembling the pulsatile release that occurs physiologically. Natural GH secretion is not continuous but instead occurs in discrete pulses, particularly during sleep and in response to exercise and fasting. Continuous GH elevation, as produced by some other secretagogues, can desensitize receptors and disrupt normal feedback. Ipamorelin produces a single, rapid GH peak modeled as zero-order release over a finite duration, with peak concentration occurring approximately 0.67 hours after intravenous administration, followed by an exponential decline [3].

Critically, the pituitary GH content is not depleted by ipamorelin at standard research doses in rat studies. This suggests the compound draws on the releasable GH pool rather than accelerating total GH synthesis beyond sustainable rates, an important distinction for research studying chronic administration effects [1].

IGF-1 Axis Activation and Downstream Signaling

GH release stimulated by ipamorelin drives hepatic IGF-1 production, the growth factor that mediates many of GH’s peripheral effects on muscle, bone, and metabolism. IGF-1 activates the mTOR (mechanistic target of rapamycin) pathway in target tissues, which increases protein synthesis rates. Ipamorelin research in rats has examined this downstream cascade as a potential mechanism underlying observed changes in tibial growth rate and body weight [1,4].

Interestingly, one rat study found that ipamorelin increased bone growth and body weight at 15 days without measurable changes in circulating IGF-1 or IGF-binding proteins. This finding raises the possibility that local IGF-1 production in target tissues, not captured by serum measurements, accounts for some effects, or that mechanisms independent of the IGF-1 axis are involved [4]. The question remains unresolved in published research.

Selectivity Profile

Ipamorelin’s most studied property is what it does not do. At doses exceeding 200 times the ED50 for GH release in rats (ED50 = 80 nmol/kg), ipamorelin does not significantly elevate ACTH, cortisol, or prolactin [1]. This profile is reproduced in the table below for direct comparison.

This selectivity makes ipamorelin a cleaner research tool when the experimental question concerns GH specifically, rather than the broader hormonal cascade triggered by earlier secretagogues.

Lipolysis and Metabolic Pathways

GH stimulated by ipamorelin activates hormone-sensitive lipase in adipose tissue, promoting lipolysis, the breakdown of stored fat. GH also improves insulin sensitivity and glucose uptake at appropriate concentrations. These downstream metabolic effects are the basis for research interest in body composition applications, though they are indirect effects of GH release rather than direct ipamorelin actions on metabolic enzymes [5].

Major Areas of Research

Ipamorelin research spans several biological systems, driven primarily by the downstream consequences of selective GH stimulation. The following areas represent current research directions in animal models and cell systems. Human data are limited to the two clinical trials described separately.

Bone Metabolism and Density Studies

Bone research represents one of ipamorelin’s most consistently demonstrated preclinical effects. A 15-day rat study using subcutaneous doses from 18 to 450 micrograms per day produced dose-dependent increases in tibial growth rate, rising from 42 micrometers per day at low doses to 52 micrometers per day at higher doses. Body weight increased proportionally. Neither IGF-1 levels nor bone marker concentrations changed significantly in serum measurements, leaving the precise mechanism of bone effects open for further study [4].

A separate 12-week glucocorticoid model established that ipamorelin reverses steroid-induced bone loss in female rats. Animals receiving glucocorticoids alongside ipamorelin showed improvements in bone mineral density, bone mineral content, and tibia length compared to controls receiving glucocorticoids alone [4].

Key Research Highlights:

• Dose-dependent tibial growth rate increases in healthy female rats over 15 days
• Reversal of glucocorticoid-induced bone mineral density loss over 12 weeks
• Bone effects observed without parallel changes in circulating IGF-1, raising mechanistic questions

Gastrointestinal Motility Research

Gastrointestinal research drove ipamorelin into clinical development. In rodent postoperative ileus models, a single intravenous dose of 0.14 micromol/kg reversed delayed gastric emptying and restored small intestinal transit toward normal values. Repetitive dosing at 0.1 to 1 mg/kg four times daily increased fecal output, food intake, and weight gain compared to vehicle controls [2].

These findings informed the Helsinn Therapeutics Phase II trial in surgical patients, which ultimately failed its primary endpoint of time to first meal intake after bowel resection surgery. The translational gap between rodent ileus models and human postoperative gut recovery represents a significant limitation for this research area, as it does for many peptide research programs where preclinical success does not reproduce in human trials [2].

Key Research Highlights:

• Single IV dose reversed delayed gastric emptying in rodent surgical models
• Repetitive dosing restored food intake and weight gain in postoperative ileus models
• Phase II human trial failed primary endpoint; gastrointestinal development discontinued

Body Composition and Muscle Research

Body composition research examines ipamorelin’s potential to alter the ratio of lean mass to fat mass through GH-mediated mechanisms. GH promotes lipolysis in adipose tissue while IGF-1 supports protein synthesis in muscle. A murine model of glucocorticoid-induced muscle loss tested ipamorelin in combination with CJC-1295, a GHRH analog, and found the combination improved tetanic tension, a measure of muscle contractile force [6]. That study evaluated the combination rather than ipamorelin alone, which limits conclusions about ipamorelin’s individual contribution to the observed effect.

Metabolic research has also explored mitochondrial bioenergetics, ATP production, and oxidative stress modulation as downstream research areas, though published peer-reviewed data in these specific areas remain limited. These are identified in the literature as research interests rather than established effects [5].

Key Research Highlights:

• GH-mediated lipolysis and IGF-1-driven protein synthesis provide theoretical basis for body composition effects
• Combination study with CJC-1295 showed improved muscle contractile force in glucocorticoid-treated mice
• Dedicated ipamorelin-only body composition studies in humans remain absent from the literature

Metabolic Function Studies

Ipamorelin’s downstream effects on metabolism are studied through GH’s established actions on insulin sensitivity and glucose regulation. GH increases glucose uptake in peripheral tissues and improves insulin sensitivity at physiological concentrations, though supraphysiological GH can paradoxically impair insulin signaling. Research models examining ipamorelin for metabolic applications focus on whether pulsatile, physiologically-patterned GH release avoids the insulin resistance seen with continuous or excessive GH exposure [5].

Aging research connects to this area because GH secretion declines with age, a phenomenon called somatopause. Ipamorelin’s ability to stimulate GH pulses in aged animal models has generated exploratory research interest in whether restoring youthful GH patterns affects age-related metabolic deterioration. No human aging studies have been conducted [7].

Key Research Highlights:

• GH stimulated by ipamorelin activates hormone-sensitive lipase and may improve insulin sensitivity at appropriate concentrations
• Aging models show GH decline with age; ipamorelin restores pulse amplitude in animal models
• Human metabolic and aging data are completely absent

Emerging Neurobiology Research

The most recent category of research interest involves indirect neurobiological effects through GH and IGF-1 signaling in the brain. GH receptors and IGF-1 receptors are expressed in neuronal populations, and both hormones support neurogenesis and neurotrophic factor production. Researchers have noted that GH secretagogues may influence cognitive resilience and neuronal maintenance through these indirect pathways [8].

Direct peer-reviewed evidence specifically for ipamorelin in neurobiological models is scarce as of the current literature. Most available commentary in this area comes from exploratory or vendor-sponsored sources rather than peer-reviewed experimental studies. This area should be treated as a hypothesis-generating direction rather than an established research finding [7,8].

Key Research Highlights:

• GH and IGF-1 receptors expressed in brain regions support theoretical neurobiological interest
• No peer-reviewed ipamorelin-specific neurobiology studies identified in current literature
• Described consistently as an area of research interest, not an established research finding

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Ipamorelin pharmacokinetics were characterized in the Phase I human trial using intravenous infusion over 15 minutes at doses ranging from 4.21 to 140.45 nmol/kg in approximately 40 healthy male volunteers. Linear pharmacokinetics were confirmed across the entire dose range tested, meaning drug exposure increased proportionally with dose without evidence of saturation or non-linear accumulation [3].

Subcutaneous administration is used in most animal studies and is the route examined in proposed compounding formulations, though formal subcutaneous bioavailability data from controlled human pharmacokinetic studies are not available in the published literature. Animal studies confirm systemic absorption and GH stimulation after subcutaneous injection.

Distribution and Metabolism

The terminal plasma half-life from the Phase I trial was approximately two hours, consistent with the enhanced stability conferred by D-amino acid incorporation and C-terminal amidation [3]. Clearance was measured at 0.078 L/h/kg.

Ipamorelin distributes to tissues expressing GHSR-1a, primarily the pituitary and hypothalamus, but GH released in response to ipamorelin acts broadly through IGF-1 production in the liver and subsequent tissue distribution. Excretion occurs primarily through renal pathways.

Pharmacodynamic Parameters

The Phase I trial provided quantitative pharmacodynamic data alongside pharmacokinetic measurements. The SC50 (concentration producing half-maximal GH stimulation) was 214 nmol/L. Maximum GH production rate reached 694 mIU/L/h. Peak GH concentration occurred approximately 0.67 hours after intravenous infusion began, consistent with rapid GHSR-1a activation followed by calcium-dependent exocytosis [3].

Inter-individual variability in GH response (pharmacodynamic variability) was greater than variability in drug exposure (pharmacokinetic variability). This means that the same blood concentration of ipamorelin produces substantially different GH responses across individuals, a finding relevant for interpreting research results across different subjects.

Delivery Methods Under Investigation

• Intravenous infusion: Used in Phase I and Phase II clinical trials; provides precise dose control and rapid pharmacokinetic characterization
• Subcutaneous injection: Standard route in animal studies; proposed route for compounding formulations at 2000 mcg/mL; systemic GH response confirmed in animal models
• Intraperitoneal injection: Used in rodent research models; rapid systemic distribution confirmed

Excretion and Clearance

Primary excretion is renal. The relatively short two-hour plasma half-life means ipamorelin clears rapidly from circulation. Biological effects mediated through GH and IGF-1 may persist longer than plasma ipamorelin levels, because GH and IGF-1 themselves have their own distinct half-lives and downstream signaling durations.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data

• Only one Phase I trial and one Phase II trial have been conducted in humans.
• The Phase II trial failed its primary endpoint, and clinical development for gastrointestinal indications was discontinued.
• No Phase II or III trials exist for any other indication.
• Safe and effective dosing parameters in humans for any application beyond the studied intravenous protocol are unknown.
• Long-term effects of repeated ipamorelin administration in humans are completely uninvestigated.

Mechanistic Understanding

• Bone growth effects observed in rat studies occurred without measurable changes in circulating IGF-1, leaving the operative mechanism unclear.
• The relative contributions of systemic versus local IGF-1 to ipamorelin’s tissue effects have not been resolved.
• Potential receptor desensitization with chronic administration was signaled in rat studies (marginal GH response reduction with repeat dosing) but has not been characterized formally.
• Emerging interest in neurobiological effects lacks peer-reviewed experimental support as of the current literature.

Methodological Considerations

• Most preclinical studies date to the late 1990s and early 2000s; replication with modern techniques and reporting standards is limited.
• Combination studies (particularly with CJC-1295) evaluate blends rather than ipamorelin alone, making it difficult to attribute specific effects to either component.
• The translational failure from rodent gastrointestinal models to human Phase II outcomes highlights the general risk of extrapolating animal model results to human applications.
• No human body composition, metabolic, bone, or aging studies exist; these remain entirely in animal models.

Areas Needing Further Investigation

• Human pharmacokinetic studies for subcutaneous administration, the most commonly discussed research route, have not been published.
• The mechanism underlying bone effects independent of measurable IGF-1 changes requires dedicated investigation.
• Desensitization kinetics with repeated administration need formal characterization before any chronic-use research can be interpreted reliably.
• Anti-aging and body composition applications are entirely theoretical in humans and require prospective clinical study.

Regulatory and Research Status

Current Classification

FDA Status Ipamorelin is not approved by the FDA for any human therapeutic use. The compound exists in a complex regulatory position for compounding purposes. Ipamorelin acetate was previously listed on the FDA’s Category 2 list of substances considered for bulk drug substance compounding in 503B outsourcing facilities. The nomination for ipamorelin acetate was withdrawn in September 2024, removing it from active Category 2 consideration. No USP or NF monograph exists for either ipamorelin free base or ipamorelin acetate [9]. Both forms remain research-use-only compounds.

WADA Status The World Anti-Doping Agency prohibits ipamorelin in competitive sport. Growth hormone secretagogues, including GHSR agonists, are listed under the prohibited category covering peptide hormones, growth factors, related substances, and mimetics. Athletes subject to anti-doping testing must not use ipamorelin regardless of administration method or claimed purpose.

International Perspective Most major regulatory jurisdictions follow similar classifications. The European Medicines Agency has not approved ipamorelin for human therapeutic use. Clinical development was discontinued after the Phase II failure, and no regulatory approval pathway is currently being pursued by any known sponsor. The compound is classified as a research chemical across major international markets.

Research Community Approach

Active preclinical research continues in academic settings examining GH axis biology, bone metabolism, and gastrointestinal physiology. Ipamorelin’s well-characterized selectivity profile makes it a useful tool for studies where clean GH stimulation without cortisol or ACTH confounding is required. Institutional oversight and appropriate biosafety protocols apply to all legitimate research use.

Future Research Directions

The most significant gap is human data beyond the narrow intravenous protocol studied in the late 1990s. Subcutaneous pharmacokinetic studies, body composition trials in GH-deficient populations, and bone density studies in glucocorticoid-treated patients all represent logical next steps based on preclinical findings. The Phase II gastrointestinal failure does not preclude investigation of other indications, but no sponsor has announced plans to pursue further clinical development as of the current literature.

Key Research Findings

Selectivity Profile Establishment (1998)

Research Focus: Comparative hormonal effects of ipamorelin versus GHRP-6 and GHRP-2 in rat and swine models Key Results: Ipamorelin stimulated GH release with potency equivalent to GHRP-6 (EC50 approximately 1.3 nmol/L in rat pituitary cells) while producing no significant elevation in ACTH, cortisol, or prolactin at doses exceeding 200 times the ED50 for GH release. GH levels rose up to 60-fold over baseline in some animal models. Significance: Established ipamorelin as the first GHRP-like agonist with GHRH-level selectivity, creating a new benchmark for growth hormone secretagogue research Limitations: Animal models only; cross-species extrapolation to humans requires caution [1]

Longitudinal Bone Growth Study in Female Rats

Research Focus: Effects of 15-day ipamorelin administration on skeletal growth and body composition Key Results: Dose-dependent increase in tibial growth rate from 42 micrometers per day at low dose to 52 micrometers per day at higher doses; proportional body weight increases; no significant changes in serum IGF-1, IGF-binding proteins, bone markers, or pituitary GH content Significance: Demonstrates bone growth potential and raises mechanistic questions about IGF-1-independent pathways; confirms pituitary GH stores are not depleted Limitations: 15-day duration only; female rats; mechanism of IGF-1-independent bone effects unresolved [4]

Glucocorticoid-Induced Bone Loss Reversal

Research Focus: 12-week treatment in female rats receiving concurrent glucocorticoids Key Results: Ipamorelin-treated animals showed improvements in bone mineral density, bone mineral content, and tibia length compared to glucocorticoid-only controls Significance: Positions ipamorelin as a research tool for studying GH-mediated protection against steroid-induced bone loss, a clinically significant problem in patients on long-term glucocorticoid therapy Limitations: Rodent model; female animals only; no human data [4]

Phase I Clinical Trial Results

Research Focus: Dose-escalation safety and pharmacokinetics in healthy male volunteers Key Results: Linear pharmacokinetics confirmed at all doses; dose-proportional GH release demonstrated; terminal half-life approximately 2 hours; SC50 of 214 nmol/L; peak GH at 0.67 hours; well-tolerated with minimal adverse effects; higher inter-individual pharmacodynamic than pharmacokinetic variability Significance: Provided the foundational human pharmacology data that informed clinical development; confirmed the selectivity profile observed in animals translates to human GH stimulation Limitations: Single administration via intravenous infusion only; male volunteers only; approximately 40 participants; no repeat-dose safety data collected [3]

Phase II Postoperative Ileus Trial

Research Focus: Randomized, double-blind, placebo-controlled trial in 117 surgical patients after bowel resection Key Results: Primary endpoint of time to first meal intake post-surgery not met; no significant difference in measurable colonic function parameters between ipamorelin acetate (0.03 mg/kg) and placebo; compound was well-tolerated for up to 7 days of inpatient administration Significance: Demonstrated that preclinical gastrointestinal motility restoration in rodent models did not translate to clinically meaningful benefit in human postoperative ileus; clinical development for this indication discontinued Limitations: Single indication tested; route and dose were intravenous and may not represent optimal parameters; primary endpoint selection may not have captured all relevant clinical effects [2]

CJC-1295 Combination Study

Research Focus: Combined GH secretagogue treatment in murine model of glucocorticoid-induced muscle loss Key Results: CJC-1295 plus ipamorelin combination improved tetanic tension (muscle contractile force) compared to glucocorticoid-treated controls Significance: Provides rationale for studying combined GHRH analog and GHSR agonist approaches in muscle wasting research, leveraging complementary mechanisms of the two GH axis pathways Limitations: Combination study only; individual ipamorelin contribution cannot be isolated; murine model; glucocorticoid-induced rather than naturally occurring muscle loss [6]

Frequently Asked Questions

What is ipamorelin and how is it different from other growth hormone peptides?

Ipamorelin is a synthetic five-amino acid peptide that stimulates the pituitary gland to release growth hormone by binding to the ghrelin receptor (GHSR-1a). Its key difference from earlier growth hormone peptides like GHRP-6 and GHRP-2 is selectivity: ipamorelin stimulates GH release without raising cortisol, ACTH, or prolactin, even at very high doses in animal studies. This cleaner hormonal profile makes it a useful research tool when scientists want to study GH effects specifically.

What has research shown about ipamorelin’s effects on bone?

Animal studies in rats showed that ipamorelin increased tibial growth rates in a dose-dependent way and reversed bone mineral density loss caused by glucocorticoid (steroid) treatment over 12 weeks. Interestingly, these bone effects occurred without detectable changes in blood IGF-1 levels, which raises unresolved questions about the precise biological mechanism. No human bone studies have been conducted with ipamorelin.

Has ipamorelin been tested in human clinical trials?

Yes. A Phase I trial in approximately 40 healthy male volunteers confirmed that ipamorelin produces dose-proportional GH release and is well-tolerated when given intravenously. A subsequent Phase II trial tested ipamorelin in 117 patients recovering from bowel resection surgery to see whether it could restore gut function faster. That trial failed to meet its primary endpoint, and clinical development was discontinued. No further human trials are currently registered.

Is ipamorelin approved for any use?

Ipamorelin is not approved by the FDA or any major regulatory agency for human therapeutic use. It is classified as a research-use-only compound. It was previously listed for consideration in compounding pharmacy formulations, but that nomination was withdrawn in September 2024. The World Anti-Doping Agency also prohibits ipamorelin in competitive sport under its category covering growth hormone-related substances.

How does ipamorelin compare to CJC-1295 as a research peptide?

The two compounds work through different pathways within the GH axis. Ipamorelin activates the ghrelin receptor (GHSR-1a) on pituitary cells directly, while CJC-1295 is a GHRH analog that acts on growth hormone-releasing hormone receptors. Their plasma half-lives differ substantially: ipamorelin clears in approximately 2 hours, while CJC-1295 with DAC has a half-life of 5 to 8 days. Because they stimulate GH release through different receptors, researchers study them both separately and in combination, where they may produce additive effects on GH output.

References

1. Raun, K., Hansen, B.S., Johansen, N.L., Thogersen, H., Madsen, K., Ankersen, M., & Andersen, P.H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PubMed

2. Poitras, P., Polvino, W., & Coupal, L. (2005). Gastro-intestinal effect of ghrelin agonist RC-1139 in the rat: Effect on delayed gastric emptying and post-operative ileus. Peptides, 26(9), 1598-1601. PubMed

3. Svensson, J., Lall, S., Dickson, S.L., Bengtsson, B.A., Romer, J., Ahnfelt-Ronne, I., Ohlsson, C., & Jansson, J.O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology, 165(3), 569-577. PubMed

4. Johansen, P.B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T.T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone and IGF Research, 9(2), 106-113. PubMed

5. Nass, R., Pezzoli, S.S., Oliveri, M.C., Patrie, J.T., Harrell, F.E., Clasey, J.L., Heymsfield, S.B., Bach, M.A., Vance, M.L., & Thorner, M.O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601-611. PubMed

6. Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Frohman, L.A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. PubMed

7. Veldhuis, J.D., Patrie, J.T., Frick, K., Anderson, S.M., & Johnson, M.L. (2004). Administration of estradiol and testosterone to healthy aging men subverts the growth hormone (GH) dose-response relationship for the GH-releasing peptide-2 stimulation of GH secretion. Journal of Clinical Endocrinology and Metabolism, 89(8), 3657-3665. PubMed

8. Frago, L.M., & Chowen, J.A. (2021). Involvement of astrocytes in growth hormone and insulin-like growth factor-I signaling. Frontiers in Endocrinology, 12, 632319. PubMed

9. U.S. Food and Drug Administration. (2024). Bulk drug substances nominated for use in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act. FDA. FDA

10. Ankersen, M., Johansen, N.L., Madsen, K., Hansen, T.K., & Raun, K. (1998). Discovery of a series of non-peptide growth hormone secretagogues with benzamide-based structures. Journal of Medicinal Chemistry, 41(17), 3124-3134. PubMed

11. Ghigo, E., Arvat, E., Ramunni, J., Colao, A., Gianotti, L., Deghenghi, R., Lombardi, G., & Camanni, F. (1997). Adrenocorticotropin and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and in patients with Cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism, 82(8), 2439-2444. PubMed

12. Broglio, F., Gottero, C., Benso, A., Prodam, F., Destefanis, S., Gauna, C., Maccario, M., Deghenghi, R., van der Lely, A.J., & Ghigo, E. (2003). Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. Journal of Clinical Endocrinology and Metabolism, 88(9), 4268-4272. PubMed

13. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656-660. PubMed

14. Smith, R.G., Pong, S.S., Hickey, G., Jacks, T., Cheng, K., Leonard, R., Cohen, C.J., Arena, J.P., Chang, C.H., Drisko, J., Wyvratt, M., Fisher, M., Nargund, R., & Patchett, A. (1996). Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Progress in Hormone Research, 51, 261-286. PubMed

15. Sigalos, J.T., & Pastuszak, A.W. (2018). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 6(1), 45-53. PubMed

16. Walker, R.F. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307-308. PubMed

17. Svensson, J., Lall, S., Dickson, S.L., Bengtsson, B.A., Romer, J., Ahnfelt-Ronne, I., Ohlsson, C., & Jansson, J.O. (2000). Effects of GH and IGF-I on growth plate and bone. Journal of Endocrinology, 164(1), R1-6. PubMed